Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NKTR
SellHot AirNektar Therapeutics · Healthcare · United States · $2.5B · Avg Vol: $42M/d
COMPANY DESCRIPTION
Nektar Therapeutics is a biopharmaceutical company focused on developing innovative new medicines for serious diseases including cancer, autoimmune conditions, and chronic pain. The company differentiates itself through its proprietary polymer conjugation technology platform, which is designed to improve the therapeutic properties of small molecules and biologics, addressing significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.1M | 90.1M | 98.4M | 55.2M | -15.7% | 54.6M | 41.9M | 57.0M | 1.6% |
| EPS | -10.99 | -8.21 | -3.19 | -9.73 | — | -6.12 | -8.47 | -10.84 | — |
| Shares | 33.8M | 33.8M | 33.8M | 20.4M | -39.7% | — | — | — | — |
| Debt | 131.5M | 117.8M | 102.6M | 85.8M | -13.3% | 135.9M | — | — | — |
| Equity | 366.6M | 131.0M | 60.7M | 89.8M | -37.4% | — | — | — | — |
| Op CF | -304.0M | -192.6M | -175.7M | -208.5M | — | -233.8M | — | — | — |
| Inv CF | 365.8M | 139.6M | 142.6M | -1.2M | — | — | — | — | — |
| Fin CF | 1.5M | 30.0K | 42.1M | 180.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NKTR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NKTR | Nektar Therapeutics(you) | $2.5B | 23 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
| PGEN | Precigen, Inc. | $2.5B | 28 | Sell |
| RAPP | Rapport Therapeutics, Inc. | $2.3B | 19 | Strong Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| XNCR | Xencor, Inc. | $1.9B | 25 | Sell |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | 25 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%